TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF GLOBAL LUNG CANCER THERAPEUTICS MARKET 44
1.4 CURRENCY AND PRICING 46
1.5 LIMITATIONS 46
1.6 MARKETS COVERED 47
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 RESEARCH METHODOLOGY 54
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57
2.7 DBMR MARKET POSITION GRID 58
2.8 DBMR MARKET CHALLENGE MATRIX 60
2.9 DBMR VENDOR SHARE ANALYSIS 61
2.10 MULTIVARIATE MODELLING 61
2.11 PRODUCT TIME LINE 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 MARKET OVERVIEW 64
3.1 DRIVERS 66
3.1.1 INCREASING CASES OF LUNG CANCER 66
3.1.2 GROWING NUMBER OF SMOKERS 67
3.1.3 GOVERNMENT / ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS 68
3.1.4 INCREASING AWARENESS 68
3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES 69
3.2 RESTRAINS 70
3.2.1 PRICING PRESSURE 70
3.2.2 HIGH COST 71
3.3 OPPORTUNITIES 72
3.3.1 APPROVALS AND PRODUCT PIPEPLINE 72
3.3.2 HEALTH TOURISM 73
3.3.3 NEW PRODUCT LAUNCHES 74
?
3.4 CHALLENGES 75
3.4.1 SIDE EFFECTS 75
3.4.2 LACK OF NUMBER OF ONCOLOGISTS 76
3.4.3 UNMET MEDICAL NEEDS 76
4 EXECUTIVE SUMMARY 77
5 PREMIUM INSIGHTS 81
6 EPIDEMIOLOGY OF LUNG CANCER 83
7 REGULATORY PROCEDURE 86
8 PIPELINE DRUGS 88
9 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE 92
9.1 OVERVIEW 93
9.2 NON-SMALL CELL LUNG CANCER 94
9.2.1 SQUAMOUS CELL CARCINOMA 95
9.2.2 PULMONARY ADENOCARCINOMA 96
9.2.3 ADENOSQUAMOUS CARCINOMA (ASC) 96
9.2.4 LARGE CELL CARCINOMA 96
9.2.5 SARCOMATOID CARCINOMA 97
9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER 97
9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA 97
9.2.7.1 ADENOID CYSTIC CARCINOMA 98
9.2.7.2 MUCOEPIDERMOID CARCINOMA 98
9.2.7.3 ACINIC CELL CARCINOMA 98
9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA 98
9.2.7.5 GRANULAR CELL LUNG TUMORS 98
9.3 METASTATIC LUNG CANCER 99
9.4 MESOTHELIOMA 100
9.5 CHEST WALL TUMORS 101
9.5.1 PRIMARY TUMORS 101
9.5.2 METASTATIC TUMORS 101
9.5.3 SARCOMAS 102
9.6 PULMONARY NEUROENDOCRINE TUMORS 102
9.6.1 CARCINOID TUMORS 103
9.6.1.1 TYPICAL CARCINOID TUMORS 103
9.6.1.2 ATYPICAL CARCINOID TUMORS 103
9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA 103
9.6.3 SMALL-CELL LUNG CANCER 104
9.6.3.1 SMALL CELL CARCINOMA 104
9.6.3.2 COMBINED SMALL CELL CARCINOMA 104
9.7 MEDIASTINAL TUMORS 105
9.7.1 GERM CELL TUMORS 106
9.7.2 LYMPHOMAS 106
9.7.3 THYMOMAS 106
10 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE 107
10.1 OVERVIEW 108
10.2 SMALL MOLECULE 110
10.3 BILOGICS 111
11 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS 112
11.1 OVERVIEW 113
11.2 ALKYLATING AGENTS 114
11.3 ANTIMETABOLITES 115
11.4 MITOTIC INHIBITORS 116
11.5 MULTIKINASE INHIBITORS 117
11.6 EGFR INHIBITORS 118
11.7 OTHERS 118
12 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE 119
12.1 OVERVIEW 120
12.2 RADIATION THERAPY 121
12.2.1 EXTERNAL BEAM 122
12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY) 122
12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) 122
12.2.4 STEREOTACTIC RADIOSURGERY (SRS) 122
12.3 CHEMOTHERAPY 123
12.3.1 CISPLATIN 124
12.3.2 PACLITAXEL (TAXOL) 124
12.3.3 VINORELBINE (NAVELBINE) 124
12.3.4 DOCETAXEL (TAXOTERE) 124
12.3.5 ALIMTA 124
12.3.6 GEMCITABINE (GEMZAR) 124
12.3.7 DURVALUMAB (IMFINZI) 124
12.3.8 OTHERS 124
12.4 TARGETED THERAPY 125
12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS 126
12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS 126
12.4.3 ANTI-ANGIOGENESIS THERAPY 126
12.4.4 MONOCLONAL ANTIBODIES 126
12.4.5 OTHERS 126
12.5 IMMUNOTHERAPY 127
12.5.1 ATEZOLIZUMAB (TECENTRIQ) 128
12.5.2 DURVALUMAB (IMFINZI) 128
12.5.3 NIVOLUMAB (OPDIVO) 128
12.5.4 PEMBROLIZUMAB (KEYTRUDA) 128
12.6 OTHERS 128
13 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE 129
13.1 OVERVIEW 130
13.2 SINGLE DRUG THERAPY 131
13.3 COMBINATION THERAPY 132
14 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY END USER 133
14.1 OVERVIEW 134
14.2 HOSPITALS 135
14.3 SPECIALTY CLINICS 136
14.4 HOMECARE 137
14.5 OTHERS 138
15 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 139
15.1 OVERVIEW 140
15.2 HOSPITAL PHARMACY 141
15.3 RETAIL PHARMACY 142
15.4 ONLINE 142
15.5 OTHERS 143
16 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY 144
16.1 OVERVIEW 145
16.2 NORTH AMERICA 150
16.2.1 U.S. 159
16.2.2 CANADA 165
16.2.3 MEXICO 171
16.3 EUROPE 177
16.3.1 GERMANY 186
16.3.2 FRANCE 192
16.3.3 U.K. 198
16.3.4 ITALY 204
16.3.5 SPAIN 210
16.3.6 SWITZERLAND 216
16.3.7 NETHERLANDS 222
16.3.8 BELGIUM 228
16.3.9 RUSSIA 234
16.3.10 TURKEY 240
16.3.11 REST OF EUROPE 246
16.4 ASIA-PACIFIC 247
16.4.1 JAPAN 256
16.4.2 CHINA 262
16.4.3 INDIA 268
16.4.4 AUSTRALIA 274
16.4.5 SOUTH KOREA 280
16.4.6 INDONESIA 286
16.4.7 THAILAND 292
16.4.8 MALAYSIA 298
16.4.9 SINGAPORE 304
16.4.10 PHILIPPINES 310
16.4.11 REST OF ASIA-PACIFIC 316
16.5 SOUTH AMERICA 317
16.5.1 BRAZIL 326
16.5.2 REST OF SOUTH AMERICA 332
16.6 MIDDLE EAST AND AFRICA 333
16.6.1 SOUTH AFRICA 342
16.6.2 REST OF MIDDLE EAST AND AFRICA 348
17 GLOBAL LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE 349
17.1 COMPANY SHARE ANALYSIS: GLOBAL 349
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 350
17.3 COMPANY SHARE ANALYSIS: EUROPE 351
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 352
18 COMPANY PROFILES 353
18.1 F. HOFFMANN-LA ROCHE LTD 353
18.1.1 COMPANY SNAPSHOT 353
18.1.2 REVENUE ANALYSIS 353
18.1.3 GEOGRAPHICAL PRESENCE 354
18.1.4 COMPANY SHARE ANALYSIS 354
18.1.5 PRODUCT PORTFOLIO 355
18.1.6 RECENT DEVELOPMENTS 355
18.2 MERCK & CO., INC. 356
18.2.1 COMPANY OVERVIEW 356
18.2.2 REVENUE ANALYSIS 356
18.2.3 GEOGRAPHICAL PRESENCE 357
18.2.4 COMPANY SHARE ANALYSIS 357
18.2.5 PRODUCT PORTFOLIO 358
18.2.6 RECENT DEVELOPMENTS 358
18.3 BRISTOL-MYERS SQUIBB COMPANY 359
18.3.1 COMPANY OVERVIEW 359
18.3.2 REVENUE ANALYSIS 359
18.3.3 GEOGRAPHICAL PRESENCE 360
18.3.4 COMPANY SHARE ANALYSIS 360
18.3.5 PRODUCT PORTFOLIO 361
18.3.6 RECENT DEVELOPMENTS 361
18.4 ASTRAZENECA 362
18.4.1 COMPANY SNAPSHOT 362
18.4.2 REVENUE ANALYSIS 362
18.4.3 GEOGRAPHICAL PRESENCE 363
18.4.4 COMPANY SHARE ANALYSIS 363
18.4.5 PRODUCT PORTFOLIO 364
18.4.6 RECENT DEVELOPMENTS 364
18.5 ELI LILLY AND COMPANY 365
18.5.1 COMPANY SNAPSHOT 365
18.5.2 REVENUE ANALYSIS 365
18.5.3 GEOGRAPHICAL PRESENCE 366
18.5.4 COMPANY SHARE ANALYSIS 366
18.5.5 PRODUCT PORTFOLIO 367
18.5.6 RECENT DEVELOPMENTS 367
18.6 ALLERGAN 368
18.6.1 COMPANY OVERVIEW 368
18.6.2 REVENUE ANALYSIS 368
18.6.3 GEOGRAPHICAL PRESENCE 369
18.6.4 PRODUCT PORTFOLIO 369
18.6.5 RECENT DEVELOPMENTS 370
18.7 AMGEN INC. 371
18.7.1 COMPANY OVERVIEW 371
18.7.2 REVENUE ANALYSIS 371
18.7.3 GEOGRAPHICAL PRESENCE 372
18.7.4 PRODUCT PORTFOLIO 372
18.7.5 RECENT DEVELOPMENTS 373
18.8 ASTELLAS PHARMA INC. 374
18.8.1 COMPANY OVERVIEW 374
18.8.2 REVENUE ANALYSIS 374
18.8.3 GEOGRAPHICAL PRESENCE 375
18.8.4 PRODUCT PORTFOLIO 375
18.8.5 RECENT DEVELOPMENTS 376
18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 377
18.9.1 COMPANY OVERVIEW 377
18.9.2 REVENUE ANALYSIS 377
18.9.3 GEOGRAPHICAL PRESENCE 378
18.9.4 PRODUCT PORTFOLIO 378
18.9.5 RECENT DEVELOPMENTS 379
18.10 CELGENE CORPORATION 380
18.10.1 COMPANY OVERVIEW 380
18.10.2 REVENUE ANALYSIS 380
18.10.3 GEOGRAPHICAL PRESENCE 381
18.10.4 PRODUCT PORTFOLIO 381
18.10.5 RECENT DEVELOPMENTS 381
18.11 DR. REDDY'S LABORATORIES LTD. 382
18.11.1 COMPANY SNAPSHOT 382
18.11.2 REVENUE ANALYSIS 382
18.11.3 GEOGRAPHICAL PRESENCE 383
18.11.4 PRODUCT PORTFOLIO 383
18.11.5 RECENT DEVELOPMENTS 384
18.12 GLAXOSMITHKLINE PLC. 385
18.12.1 COMPANY OVERVIEW 385
18.12.2 REVENUE ANALYSIS 385
18.12.3 GEOGRAPHICAL PRESENCE 386
18.12.4 PRODUCT PORTFOLIO 386
18.12.5 RECENT DEVELOPMENTS 387
18.13 JOHNSON & JOHNSON SERVICES, INC. 388
18.13.1 COMPANY SNAPSHOT 388
18.13.2 REVENUE ANALYSIS 388
18.13.3 GEOGRAPHICAL PRESENCE 389
18.13.4 PRODUCT PORTFOLIO 389
18.13.5 RECENT DEVELOPMENTS 390
18.14 NOVARTIS AG 391
18.14.1 COMPANY SNAPSHOT 391
18.14.2 REVENUE ANALYSIS 391
18.14.3 GEOGRAPHICAL PRESENCE 392
18.14.4 PRODUCT PORTFOLIO 392
18.14.5 RECENT DEVELOPMENT 393
18.15 ONO PHARMACEUTICAL CO., LTD. 394
18.15.1 COMPANY OVERVIEW 394
18.15.2 REVENUE ANALYSIS 394
18.15.3 GEOGRAPHICAL PRESENCE 395
18.15.4 PRODUCT PORTFOLIO 395
18.15.5 RECENT DEVELOPMENTS 396
18.16 PFIZER INC. 397
18.16.1 COMPANY SNAPSHOT 397
18.16.2 RECENT FINANCIALS 397
18.16.3 GEOGRAPHICAL PRESENCE 398
18.16.4 PRODUCT PORTFOLIO 398
18.16.5 RECENT DEVELOPMENTS 399
18.17 SANOFI 401
18.17.1 COMPANY OVERVIEW 401
18.17.2 REVENUE ANALYSIS 401
18.17.3 GEOGRAPHICAL PRESENCE 402
18.17.4 PRODUCT PORTFOLIO 402
18.17.5 RECENT DEVELOPMENTS 403
18.18 SUMITOMO DAINIPPON PHARMA CO., LTD. 404
18.18.1 COMPANY OVERVIEW 404
18.18.2 REVENUE ANALYSIS 404
18.18.3 GEOGRAPHICAL PRESENCE 405
18.18.4 PRODUCT PORTFOLIO 405
18.18.5 RECENT DEVELOPMENTS 405
18.19 SUN PHARMACEUTICAL INDUSTRIES LTD. 407
18.19.1 COMPANY SNAPSHOT 407
18.19.2 REVENUE ANALYSIS 407
18.19.3 GEOGRAPHICAL PRESENCE 408
18.19.4 PRODUCT PORTFOLIO 408
18.19.5 RECENT DEVELOPMENTS 409
18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED 410
18.20.1 COMPANY OVERVIEW 410
18.20.2 REVENUE ANALYSIS 410
18.20.3 GEOGRAPHICAL PRESENCE 411
18.20.4 PRODUCT PORTFOLIO 411
18.20.5 RECENT DEVELOPMENTS 412
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. 413
18.21.1 COMPANY OVERVIEW 413
18.21.2 REVENUE ANALYSIS 413
18.21.3 GEOGRAPHICAL PRESENCE 414
18.21.4 PRODUCT PORTFOLIO 414
18.21.5 RECENT DEVELOPMENTS 414
19 QUESTIONNAIRE 415
20 RELATED REPORTS 422
?